DataSheet_3_Case Report: Significant Efficacy of Pyrotinib in the Treatment of Extensive Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Cutaneous Metastases: A Report of Five Cases.docx by Nan Wang (21935)

“…</p>Conclusions<p>This case series reports the significant therapeutic effect of pyrotinib on cutaneous metastases of HER2-positive BC for the first time. …”

DataSheet_5_Case Report: Significant Efficacy of Pyrotinib in the Treatment of Extensive Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Cutaneous Metastases: A Report of Five Cases.docx by Nan Wang (21935)

“…</p>Conclusions<p>This case series reports the significant therapeutic effect of pyrotinib on cutaneous metastases of HER2-positive BC for the first time. …”

DataSheet_1_Case Report: Significant Efficacy of Pyrotinib in the Treatment of Extensive Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Cutaneous Metastases: A Report of Five Cases.docx by Nan Wang (21935)

“…</p>Conclusions<p>This case series reports the significant therapeutic effect of pyrotinib on cutaneous metastases of HER2-positive BC for the first time. …”

DataSheet_4_Case Report: Significant Efficacy of Pyrotinib in the Treatment of Extensive Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Cutaneous Metastases: A Report of Five Cases.docx by Nan Wang (21935)

“…</p>Conclusions<p>This case series reports the significant therapeutic effect of pyrotinib on cutaneous metastases of HER2-positive BC for the first time. …”

DataSheet_2_Case Report: Significant Efficacy of Pyrotinib in the Treatment of Extensive Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Cutaneous Metastases: A Report of Five Cases.docx by Nan Wang (21935)

“…</p>Conclusions<p>This case series reports the significant therapeutic effect of pyrotinib on cutaneous metastases of HER2-positive BC for the first time. …”

DataSheet_6_Case Report: Significant Efficacy of Pyrotinib in the Treatment of Extensive Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Cutaneous Metastases: A Report of Five Cases.docx by Nan Wang (21935)

“…</p>Conclusions<p>This case series reports the significant therapeutic effect of pyrotinib on cutaneous metastases of HER2-positive BC for the first time. …”

Amount of LULC component change (sq km) of DNCC from 1992–2022. by Mashura Shammi (9033173)

A reduction of extra-axial (EA) tumor growth and an increase in overall survival is observed as the cell amount decreases. by Velislava Zoteva (17720500)

The number of dengue cases reported from 2018 to 2021. by Dinuka Ariyaratne (721988)

Subjects:

Descriptives of study variables in cases and controls. by Daniella Justesen (22170253)

Subjects:

Case outcomes, signs, and symptoms from electronically reported RMSF cases, 2011–2019. by Anne M. Kjemtrup (9922343)

Subjects:

Distribution of the amount of physical activity recorded during head-raising movements. by Akihiro Ohnishi (10989900)

Subjects:

The reported cases of AEs at each SOC level. by Xiangpeng Li (1750972)

Image 1_Case Report: Idiopathic myointimal hyperplasia of mesenteric veins mimicking inflammatory bowel disease: a case report with literature review.tif by Wei Wang (17594)

Image 2_Case Report: Idiopathic myointimal hyperplasia of mesenteric veins mimicking inflammatory bowel disease: a case report with literature review.tif by Wei Wang (17594)

Decrease in METH-evoked DA release in the nucleus accumbens in <i>Ptprz</i>-KO mice. by Akihiro Fujikawa (122649)

Reported 1256 HCV cases by risk behavior. by Liton Chandra Deb (12316758)

Trend of TI values with age: The TI values decreased significantly with the increase of age, * p<0.01 vs other groups. by Yunmeng Da (707943)

Reported cases of ADEs per SOC level. by Chengkai Yang (2854457)

Subjects:

Image_1_Case report: A case of duodenal adenocarcinoma achieving significantly long survival treating with immune checkpoint inhibitors and chemotherapy without positive biomarkers.tif by Xian Chen (107385)

“…Currently, chemotherapy is the most used treatment; however, it has a poor median progression-free survival (mPFS) of no more than five months in the second-line setting. We report a case with DA that responded well to the immune checkpoint inhibitor (ICI) tislelizumab plus irinotecan in the second-line treatment. …”